PRIMARY STUDY
Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders
Key Findings: The reviewers conclude that cannabinoids, in particular CBD, improves symptoms associated with common co-morbidities in ASD's. In addition, cannabinoid-based therapeutics is associated with low adverse effects and a reduction in concomitant medication.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Portugal
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Citation: Carreira LD, et al. Clinical Data on Canabinoids: Translational Research in the Treatment of Autism Spectrum Disorders. Biomedicines. 2022; 10:(unknown pages). doi: 10.3390/biomedicines10040796
Authors: Carreira LD, Matias FC, Campos MG
